Issue

Vol. 11 (2019)

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy

https://doi.org/10.1007/s40820-019-0305-x
Jie Wang
Department of Pharmaceutical Engineering and Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, People’s Republic of China
Lan Fang
Department of Pharmaceutical Engineering and Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, People’s Republic of China
Ping Li
Department of Pharmaceutical Engineering and Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, People’s Republic of China
Lang Ma
Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustrasse 3, 14195 Berlin, Germany
Weidan Na
Department of Pharmaceutical Engineering and Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, People’s Republic of China
Chong Cheng
Institute of Chemistry and Biochemistry, Freie Universität Berlin, Takustrasse 3, 14195 Berlin, Germany
Yueqing Gu
Department of Pharmaceutical Engineering and Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, People’s Republic of China
Dawei Deng
Department of Pharmaceutical Engineering and Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, People’s Republic of China

Corresponding Author: Dawei Deng

dengdawei@cpu.edu.cn

Nano-Micro Letters, Vol. 11 (2019), Article Number: 74

Abstract

Recently emerged cancer immunochemotherapy has provided enormous new possibilities to replace traditional chemotherapy in fighting tumor. However, the treatment efficacy is hampered by tumor hypoxia-induced immunosuppression in tumor microenvironment (TME). Herein, we fabricated a self-oxygenation/degradable inorganic nanozyme with a core–shell structure to relieve tumor hypoxia in cancer immunochemotherapy. By integrating the biocompatible CaO2 as the oxygen-storing component, this strategy is more effective than the earlier designed nanocarriers for delivering oxygen or H2O2, and thus provides remarkable oxygenation and long-term capability in relieving hypoxia throughout the tumor tissue. Consequently, in vivo tests validate that the delivery system can successfully relieve hypoxia and reverse the immunosuppressive TME to favor antitumor immune responses, leading to enhanced chemoimmunotherapy with cytotoxic T lymphocyte-associated antigen 4 blockade. Overall, a facile, robust and effective strategy is proposed to improve tumor oxygenation by using self-decomposable and biocompatible inorganic nanozyme reactor, which will not only provide an innovative pathway to relieve intratumoral hypoxia, but also present potential applications in other oxygen-favored cancer therapies or oxygen deficiency-originated diseases.


Highlights:


1 Self-oxygenation/degradable nanozyme reactors with core–shell structure were fabricated for relieving tumor hypoxia.
2 Intratumoral hypoxia alleviation and sensitization of immunochemotherapy using as-prepared nanozyme reactors was demonstrated in B16F10 melanoma tumor.

Keywords

Inorganic nanozyme Self-oxygenation nanoreactor Biodegradable nanomedicine Immunochemotherapy Cancer treatment
Wang, Jie, Lan Fang, Ping Li, Lang Ma, Weidan Na, Chong Cheng, Yueqing Gu, and Dawei Deng. 2019. “Inorganic Nanozyme With Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy”. Nano-Micro Letters 11 (September):74. https://doi.org/10.1007/s40820-019-0305-x.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. H. Wang, D.J. Mooney, Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17(9), 761–772 (2018). https://doi.org/10.1038/s41563-018-0147-9
  2. Y. Chen, R. Xia, Y. Huang, W. Zhao, J. Li et al., An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat. Commun. 7, 13443 (2016). https://doi.org/10.1038/ncomms13443
  3. P. Sharma, S. Hu-Lieskovan, J.A. Wargo, A. Ribas, Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4), 707–723 (2017). https://doi.org/10.1016/j.cell.2017.01.017
  4. D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423 (2013). https://doi.org/10.1038/nm.3394
  5. J.-N. Liu, W. Bu, J. Shi, Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia. Chem. Rev. 117(9), 6160–6224 (2017). https://doi.org/10.1021/acs.chemrev.6b00525
  6. N. Li, L. Yu, J. Wang, X. Gao, Y. Chen, W. Pan, B. Tang, A mitochondria-targeted nanoradiosensitizer activating reactive oxygen species burst for enhanced radiation therapy. Chem. Sci. 9(12), 3159–3164 (2018). https://doi.org/10.1039/C7SC04458E
  7. D. Guo, X. Ji, F. Peng, Y. Zhong, B. Chu, Y. Su, Y. He, Photostable and biocompatible fluorescent silicon nanoparticles for imaging-guided co-delivery of sirna and doxorubicin to drug-resistant cancer cells. Nano-Micro Lett. 11, 27 (2019). https://doi.org/10.1007/s40820-019-0257-1
  8. D. Huo, S. Liu, C. Zhang, J. He, Z. Zhou, H. Zhang, Y. Hu, Hypoxia-targeting, tumor microenvironment responsive nanocluster bomb for radical-enhanced radiotherapy. ACS Nano 11(10), 10159–10174 (2017). https://doi.org/10.1021/acsnano.7b04737
  9. D. Lukashev, B. Klebanov, H. Kojima, A. Grinberg, A. Ohta et al., Cutting edge: hypoxia-inducible factor 1α and its activation-inducible short isoform I. 1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J. Immunol. 177(8), 4962–4965 (2006). https://doi.org/10.4049/jimmunol.177.8.4962
  10. A. Ohta, R. Diwanji, R. Kini, M. Subramanian, A. Ohta, M. Sitkovsky, In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment. Front. Immunol. 2, 27 (2011). https://doi.org/10.3389/fimmu.2011.00027
  11. R.K. Jain, Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5), 605–622 (2014). https://doi.org/10.1016/j.ccell.2014.10.006
  12. M.V. Sitkovsky, S. Hatfield, R. Abbott, B. Belikoff, D. Lukashev, A. Ohta, Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2(7), 598–605 (2014). https://doi.org/10.1158/2326-6066.Cir-14-0075
  13. W.R. Wilson, M.P. Hay, Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393 (2011). https://doi.org/10.1038/nrc3064
  14. J. Liu, L. Tian, R. Zhang, Z. Dong, H. Wang, Z. Liu, Collagenase-encapsulated ph-responsive nanoscale coordination polymers for tumor microenvironment modulation and enhanced photodynamic nanomedicine. ACS Appl. Mater. Interfaces 10(50), 43493–43502 (2018). https://doi.org/10.1021/acsami.8b17684
  15. Y. Huang, S. Goel, D.G. Duda, D. Fukumura, R.K. Jain, Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73(10), 2943–2948 (2013). https://doi.org/10.1158/0008-5472.Can-12-4354
  16. Z. Zhou, B. Zhang, S. Wang, W. Zai, A. Yuan, Y. Hu, J. Wu, Perfluorocarbon nanoparticles mediated platelet blocking disrupt vascular barriers to improve the efficacy of oxygen-sensitive antitumor drugs. Small 14(45), 1801694 (2018). https://doi.org/10.1002/smll.201801694
  17. M. Thiel, A. Chouker, A. Ohta, E. Jackson, C. Caldwell et al., Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol. 3(6), e174 (2005). https://doi.org/10.1371/journal.pbio.0030174
  18. S.M. Hatfield, J. Kjaergaard, D. Lukashev, B. Belikoff, T.H. Schreiber et al., Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. 92(12), 1283–1292 (2014). https://doi.org/10.1007/s00109-014-1189-3
  19. S.M. Hatfield, J. Kjaergaard, D. Lukashev, T.H. Schreiber, B. Belikoff et al., Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med. 7(277), 277ra230 (2015). https://doi.org/10.1126/scitranslmed.aaa1260
  20. S. Gao, H. Lin, H. Zhang, H. Yao, Y. Chen, J. Shi, Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv. Sci. 6(3), 1801733 (2019). https://doi.org/10.1002/advs.201801733
  21. J. Wang, Y. Zhang, E. Archibong, F.S. Ligler, Z. Gu, Leveraging H2O2 levels for biomedical applications. Adv. Biosyst. 1(9), 1700084 (2017). https://doi.org/10.1002/adbi.201700084
  22. D. Deng, C. Hao, S. Sen, C. Xu, P. Král, N.A. Kotov, Template-free hierarchical self-assembly of iron diselenide nanoparticles into mesoscale hedgehogs. J. Am. Chem. Soc. 139(46), 16630–16639 (2017). https://doi.org/10.1021/jacs.7b07838
  23. D. Deng, Y. Chen, J. Cao, J. Tian, Z. Qian, S. Achilefu, Y. Gu, High-quality CuInS2/ZnS quantum dots for in vitro and in vivo bioimaging. Chem. Mater. 24(15), 3029–3037 (2012). https://doi.org/10.1021/cm3015594
  24. C. Cheng, S. Li, A. Thomas, N.A. Kotov, R. Haag, Functional graphene nanomaterials based architectures: biointeractions, fabrications, and emerging biological applications. Chem. Rev. 117(3), 1826–1914 (2017). https://doi.org/10.1021/acs.chemrev.6b00520
  25. P.N. Manghnani, W. Wu, S. Xu, F. Hu, C. Teh, B. Liu, Visualizing photodynamic therapy in transgenic zebrafish using organic nanoparticles with aggregation-induced emission. Nano-Micro Lett. 10(4), 61 (2018). https://doi.org/10.1007/s40820-018-0214-4
  26. C.R. Gordijo, A.Z. Abbasi, M.A. Amini, H.Y. Lip, A. Maeda et al., Design of hybrid MnO2-polymer-lipid nanoparticles with tunable oxygen generation rates and tumor accumulation for cancer treatment. Adv. Funct. Mater. 25(12), 1858–1872 (2015). https://doi.org/10.1002/adfm.201404511
  27. Y. Yang, L. Ma, C. Cheng, Y. Deng, J. Huang et al., Nonchemotherapic and robust dual-responsive nanoagents with on-demand bacterial trapping, ablation, and release for efficient wound disinfection. Adv. Funct. Mater. 28(21), 1705708 (2018). https://doi.org/10.1002/adfm.201705708
  28. S. Shi, F. Chen, S. Goel, S.A. Graves, H. Luo et al., In vivo tumor-targeted dual-modality PET/optical imaging with a yolk/shell-structured silica nanosystem. Nano-Micro Lett. 10(4), 65 (2018). https://doi.org/10.1007/s40820-018-0216-2
  29. G. Yang, L. Xu, Y. Chao, J. Xu, X. Sun, Y. Wu, R. Peng, Z. Liu, Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat. Commun. 8(1), 902 (2017). https://doi.org/10.1038/s41467-017-01050-0
  30. M. Song, T. Liu, C. Shi, X. Zhang, X. Chen, Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano 10(1), 633–647 (2016). https://doi.org/10.1021/acsnano.5b06779
  31. R.-Q. Li, C. Zhang, B.-R. Xie, W.-Y. Yu, W.-X. Qiu, H. Cheng, X.-Z. Zhang, A two-photon excited O2-evolving nanocomposite for efficient photodynamic therapy against hypoxic tumor. Biomaterials 194, 84–93 (2019). https://doi.org/10.1016/j.biomaterials.2018.12.017
  32. L. Meng, Y. Cheng, X. Tong, S. Gan, Y. Ding et al., Tumor oxygenation and hypoxia inducible factor-1 functional inhibition via a reactive oxygen species responsive nanoplatform for enhancing radiation therapy and abscopal effects. ACS Nano 12(8), 8308–8322 (2018). https://doi.org/10.1021/acsnano.8b03590
  33. Y. Zhang, F. Wang, C. Liu, Z. Wang, L. Kang et al., Nanozyme decorated metal–organic frameworks for enhanced photodynamic therapy. ACS Nano 12(1), 651–661 (2018). https://doi.org/10.1021/acsnano.7b07746
  34. Z. Wang, Y. Zhang, E. Ju, Z. Liu, F. Cao, Z. Chen, J. Ren, X. Qu, Biomimetic nanoflowers by self-assembly of nanozymes to induce intracellular oxidative damage against hypoxic tumors. Nat. Commun. 9(1), 3334 (2018). https://doi.org/10.1038/s41467-018-05798-x
  35. C. Yao, W. Wang, P. Wang, M. Zhao, X. Li, F. Zhang, Near-infrared upconversion mesoporous cerium oxide hollow biophotocatalyst for concurrent pH-/H2O2-responsive O2-evolving synergetic cancer therapy. Adv. Mater. 30(7), 1704833 (2018). https://doi.org/10.1002/adma.201704833
  36. T. Finkel, M. Serrano, M.A. Blasco, The common biology of cancer and ageing. Nature 448, 767–774 (2007). https://doi.org/10.1038/nature05985
  37. X. Song, J. Xu, C. Liang, Y. Chao, Q. Jin, C. Wang, M. Chen, Z. Liu, Self-supplied tumor oxygenation through separated liposomal delivery of H2O2 and catalase for enhanced radio-immunotherapy of cancer. Nano Lett. 18(10), 6360–6368 (2018). https://doi.org/10.1021/acs.nanolett.8b02720
  38. M. Thiel, C.C. Caldwell, S. Kreth, S. Kuboki, P. Chen et al., Targeted deletion of HIF-1α gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS ONE 2(9), e853 (2007). https://doi.org/10.1371/journal.pone.0000853
  39. W.-P. Li, C.-H. Su, Y.-C. Chang, Y.-J. Lin, C.-S. Yeh, Ultrasound-induced reactive oxygen species mediated therapy and imaging using a fenton reaction activable polymersome. ACS Nano 10(2), 2017–2027 (2016). https://doi.org/10.1021/acsnano.5b06175
  40. J. Wang, D. Xu, T. Deng, Y. Li, L. Xue, T. Yan, D. Huang, D. Deng, Self-decomposable mesoporous doxorubicin@ silica nanocomposites for nuclear targeted chemo-photodynamic combination therapy. ACS Appl. Nano Mater. 1(4), 1976–1984 (2018). https://doi.org/10.1021/acsanm.8b00486
  41. S. Zhang, Z. Chu, C. Yin, C. Zhang, G. Lin, Q. Li, Controllable drug release and simultaneously carrier decomposition of SiO2-drug composite nanoparticles. J. Am. Chem. Soc. 135(15), 5709–5716 (2013). https://doi.org/10.1021/ja3123015
  42. S.B. Lee, J.-E. Lee, S.J. Cho, J. Chin, S.K. Kim et al., Crushed gold shell nanoparticles labeled with radioactive iodine as a theranostic nanoplatform for macrophage-mediated photothermal therapy. Nano-Micro Lett. 11, 36 (2019). https://doi.org/10.1007/s40820-019-0266-0
  43. H. Chen, J. Tian, W. He, Z. Guo, H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J. Am. Chem. Soc. 137(4), 1539–1547 (2015). https://doi.org/10.1021/ja511420n
  44. K. Synnestvedt, G.T. Furuta, K.M. Comerford, N. Louis, J. Karhausen et al., Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Investig. 110(7), 993–1002 (2002). https://doi.org/10.1172/jci0215337
  45. H.K. Eltzschig, D. Kohler, T. Eckle, T. Kong, S.C. Robson, S.P. Colgan, Central role of sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113(1), 224–232 (2009). https://doi.org/10.1182/blood-2008-06-165746
  46. A. Palazon, A.W. Goldrath, V. Nizet, R.S. Johnson, HIF transcription factors, inflammation, and immunity. Immunity 41(4), 518–528 (2014). https://doi.org/10.1016/j.immuni.2014.09.008
  47. K.M. Mahoney, P.D. Rennert, G.J. Freeman, Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561 (2015). https://doi.org/10.1038/nrd4591
  48. G.L. Klement, Eco-evolution of cancer resistance. Sci. Transl. Med. 8(327), 327fs325 (2016). https://doi.org/10.1126/scitranslmed.aaf3802
  49. P.M. Enriquez-Navas, Y. Kam, T. Das, S. Hassan, A. Silva, P. Foroutan et al., Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8(327), 327ra324 (2016). https://doi.org/10.1126/scitranslmed.aad7842
  50. D.-W. Zheng, J.-L. Chen, J.-Y. Zhu, L. Rong, B. Li et al., Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy. Nano Lett. 16(7), 4341–4347 (2016). https://doi.org/10.1021/acs.nanolett.6b01432
  51. W. Chen, Y. Wang, M. Qin, X. Zhang, Z. Zhang, X. Sun, Z. Gu, Bacteria-driven hypoxia targeting for combined biotherapy and photothermal therapy. ACS Nano 12(6), 5995–6005 (2018). https://doi.org/10.1021/acsnano.8b02235
  52. Y.N. Zhao, X.X. Sun, G.N. Zhang, B.G. Trewyn, I.I. Slowing, V.S.-Y. Lin, Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 5(2), 1366–1375 (2011). https://doi.org/10.1021/nn103077k
  53. T. Maj, W. Wang, J. Crespo, H. Zhang, W. Wang et al., Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332 (2017). https://doi.org/10.1038/ni.3868
  54. C. Wang, Y. Ye, Q. Hu, A. Bellotti, Z. Gu, Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook. Adv. Mater. 29(29), 1606036 (2017). https://doi.org/10.1002/adma.201606036
  55. A. Facciabene, X. Peng, I.S. Hagemann, K. Balint, A. Barchetti et al., Tumour hypoxia promotes tolerance and angiogenesis via ccl28 and Treg cells. Nature 475, 226 (2011). https://doi.org/10.1038/nature10169
  56. N. Casares, M.O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202(12), 1691–1701 (2005). https://doi.org/10.1084/jem.20050915
  57. D. Hannani, A. Sistigu, O. Kepp, L. Galluzzi, G. Kroemer, L. Zitvogel, Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J. 17(5), 351–358 (2011). https://doi.org/10.1097/PPO.0b013e3182325d4d
  58. S.L. Topalian, C.G. Drake, D.M. Pardoll, Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4), 450–461 (2015). https://doi.org/10.1016/j.ccell.2015.03.001
Read More
Author biographies are not available.
Download this PDF file
PDF SUPPLEMENTARY MATERIAL
Statistic
Read Counter : 5131 Download : 3869

Most read articles by the same author(s)